ArticleCancer reports (Hoboken, N.J.)2025
Clinical and Surgical Outcome After Oncovascular Surgery of Soft Tissue and Osteogenic Sarcomas of the Limbs.
Article in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical and Surgical Outcome After Oncovascular Surgery of Soft Tissue and Osteogenic Sarcomas of the Limbs.Cancer reports (Hoboken, N.J.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundSoft tissue sarcomas (STS) and osteogenic sarcomas (OGS) of the limbs are rare diseases. Nowadays, most patients with STS or OGS undergo tumor resection and subsequent vascular reconstruction for potential limb preservation.
aimsDue to very limited data on these complex surgical procedures, the aim of this single-center, retrospective study was to evaluate the surgical and oncological outcomes of these patients.
methodsFrom 2013 to 2023, demographic, clinical, surgical, and pathological data regarding tumor disease, surgical treatment, and postoperative care of a total of 10 patients with STS and OGS were identified and analyzed. Furthermore, overall survival (OS) and freedom from tumor recurrence (FFT) were retrospectively investigated among all patients.
resultsThe mean age of the patients was 64.4 ± 22.24 years, and six women (60%) and four men (40%) were treated. Overall, 16 major arterial and venous vessels were resected and reconstructed: the lower extremity was affected in nine patients (90%). Autologous veins (n = 12, 75%), polytetrafluoroethylene (PTFE; n = 2, 12.5%), or cryopreserved allografts (n = 2, 12.5%) were mainly used for vascular reconstruction. The follow-up ranged from 7 to 60 months, with a median OS of 48 months and a median FFT of 54 months. Overall, four patients (40%) developed local tumor recurrence at the primary surgical resection site or metastasis. The primary graft patency for all vascular reconstructions was 90% at the median follow-up of 24 months. All revascularized limbs among these patients could be salvaged during the follow-up period.
conclusionTreatment of patients with STS or OGS of the limbs and subsequent vascular reconstruction can be performed safely and effectively. The outcomes described in this cohort suggest that an interdisciplinary team, including vascular surgeons and a carefully planned and rigorous clinical approach, might positively influence the postoperative and oncological outcome and limb salvage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.